9) Lynch AM, Moore M, Craig S, Lonergan PE, Martin DS and Lynch MA. (2003) Analysis of IL-1beta -induced cell signaling activation in rat hippocampus following exposure to gamma irradiation: protective effect of eicosapentaenoic acid. J Biol Chem. 51, 51075-51084
10) Martin DS, Lonergan PE, Boland B, Fogarty MP, Brady M, Horrobin DF, Campbell VA and Lynch MA (2002) Apoptotic changes in the aged brain are triggered by interleukin-1 beta -induced activation of p38 and reversed by treatment with eicosapentaenoic acid. J. Biol. Chem., 277, 34239-34246.
11) Lonergan PE, Martin DSD, Horrobin DF and Lynch MA (2002) Neuroprotective effect of eicosapentanoate in hippocampus of rats exposed to Gamma irradiation. J. Biol. Chem., 277, 20804-20811.
The information contained in this document is as of September 24, 2007.
Amarin assumes no obligation to update any forward-looking statements
contained in this document as a result of new information or future events
or developments. This document contains forward-looking statements about
Amarin's financial condition, results of operations, business prospects and
products in research that involve substantial risks and uncertainties. You
can identify these statements by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe" and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance
or events. Among the factors that could cause actual results to differ
materially from those described or projected herein are the following: the
success of Amarin's research and development activities; decisions by
regulatory authorities regarding whether and when to approve Amarin's drug
applications, as well as their decisions regarding labeling and other
matters that could affect the commercial potential of Amarin
|SOURCE Amarin Corporation Plc|
Copyright©2007 PR Newswire.
All rights reserved